Grant Number:	5U01CA088202-04 Interpret this number
Primary Investigator:	Habbema, J
Organization:	Erasmus University Of Rotterdam
Project Title:	Surveillance of Breast Cancer Trends Bij Miscan
Fiscal Year:	2003

It is difficult to assess the impact of cancer interventions on population level directly. Models may be appropriate tools for investigating different possible explanations for observed cancer incidence and mortality. This asks for models that are applicable in different populations. The microsimulation model MISCAN is applicable in different populations to evaluate the impact of breast cancer interventions. In the MISCAN model it is possible to specify demographic, epidemiological and economic information and also screening and other information such as risk factors, treatment practice and behavioral aspects. In this way insight can be gained concerning to what extent the observed trends in incidence and mortality of breast cancer can be explained by screening. Also the effects of other factors as changes in breast cancer awareness, differences in breast cancer risk by birth cohort, and changes in treatment will be studied. Furthermore, the MISCAN breast model can be used to predict effects of future cancer control strategies on population level. These results will be valuable for public health policy making and may have major impact on morbidity and mortality of breast cancer.




Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.
Authors: Alagoz O. , Berry D.A. , de Koning H.J. , Feuer E.J. , Lee S.J. , Plevritis S.K. , Schechter C.B. , Stout N.K. , Trentham-Dietz A. , Mandelblatt J.S. , et al. .
Source: Medical Decision Making : An International Journal Of The Society For Medical Decision Making, 2018 Apr; 38(1_suppl), p. 3S-8S.
PMID: 29554472
Related Citations

The MISCAN-Fadia continuous tumor growth model for breast cancer.
Authors: Tan S.Y. , van Oortmarssen G.J. , de Koning H.J. , Boer R. , Habbema J.D. .
Source: Journal Of The National Cancer Institute. Monographs, 2006; (36), p. 56-65.
PMID: 17032895
Related Citations

Effect of screening and adjuvant therapy on mortality from breast cancer.
Authors: Berry D.A. , Cronin K.A. , Plevritis S.K. , Fryback D.G. , Clarke L. , Zelen M. , Mandelblatt J.S. , Yakovlev A.Y. , Habbema J.D. , Feuer E.J. , et al. .
Source: The New England Journal Of Medicine, 2005-10-27 00:00:00.0; 353(17), p. 1784-92.
PMID: 16251534
Related Citations

Identification of mammaglobin as a novel serum marker for breast cancer.
Authors: Bernstein J.L. , Godbold J.H. , Raptis G. , Watson M.A. , Levinson B. , Aaronson S.A. , Fleming T.P. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2005-09-15 00:00:00.0; 11(18), p. 6528-35.
PMID: 16166429
Related Citations